Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

BMC Cancer · 2016 · PMC4902930 · PMID 27286871

Europe PMC DOI

hedged sentence

0.0005

closest p · 0.0× alpha

0.0005

boldest claim

The sentences

an increasing trendp = 0.0005actually significant

a decreasing trendp = 0.0061actually significant

Amongst treated patients, there was a decreasing trend in sunitinib use over time ( p = 0.0061), and an increasing trend in pazopanib use ( p = 0.0005).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.